Minerva Neurosciences (NERV) Income from Continuing Operations (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Income from Continuing Operations came in at 32311950.0 in Q1 2026, down 762.9% YoY from 4874365.64 in Q1 2025, and down 466.37% on a QoQ basis from 5705066.0 in Q4 2025.
Powered by 
Analysis
Minerva Neurosciences (NERV) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Income from Continuing Operations data on file, last reported at 32311950.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 762.9% year-over-year to 32311950.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43992202.0 (up 61.43% YoY) and the FY2025 annual result came in at 113825531.0, up 2.4% from the prior year.
- Income from Continuing Operations retreated to 32311950.0 in Q1 2026, from 5705066.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2737708.0 in Q3 2025 to a low of 103680119.0 in Q4 2023.
- A 5-year average of 23615676.29 and a median of 6176372.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations jumped 94.31% — and 2026, when it tumbled 762.9%.
- Tracing NERV's Income from Continuing Operations over 5 years: stood at 94881575.0 in 2022, then fell by 9.27% to 103680119.0 in 2023, then climbed by 3.22% to 100336784.0 in 2024, then jumped by 94.31% to 5705066.0 in 2025, then tumbled by 466.37% to 32311950.0 in 2026.
- The last three Income from Continuing Operations figures came in at 32311950.0 (Q1 2026), 5705066.0 (Q4 2025), and 2737708.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | -10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.07 Mn |
| Mar 31, 2026 | -16.04 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.92 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -6.81 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -4.15 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -4.77 Mn |
| Sep 30, 2022 | -5.03 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -7.98 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.51 Mn |